Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis.
Saved in:
| Title: | Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis. |
|---|---|
| Authors: | Zhu Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China., Zhou X; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China., Liu K; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China., Zhu H; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. zhuhong719@csu.edu.cn.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. zhuhong719@csu.edu.cn. |
| Source: | Journal of ovarian research [J Ovarian Res] 2026 Jan 28; Vol. 19 (1). Date of Electronic Publication: 2026 Jan 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1757-2215 |
|---|---|
| DOI: | 10.1186/s13048-026-01988-0 |
